Reimbursement Strategy
PPi HC individual country reimbursement expertise supports an international approach to commercialisation based on addressing the respective national, regional and local level considerations.
When entering a new market, knowledge of the market and of the related payment system is crucial to achieving reimbursement and, ultimately, commercial success. Healthcare companies need to assess the coverage and evidence requirements, coding issues and payment for each product across each setting of care. Working together with our clients, we tailor business strategies for pharmaceutical, medical device and diagnostic products to achieve maximum reimbursement potential. Our seasoned team of consultants have a proven track record in alignment of reimbursement strategies with commercial goals, so that the coverage can be used as a later marketing strength. Our perspective ranges from national to local level, so that all the milestones required for optimal reimbursement can be addressed right after a product obtains its marketing authorization.
Services
TESTIMONIALS
“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”
Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.
“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”
Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma
“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
